Page last updated: 2024-11-05

iopydone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

Iopydone is a contrast agent used in X-ray imaging, particularly in cholangiography. It is a derivative of iodized fatty acids, specifically a triiodinated derivative of poppyseed oil. Iopydone is administered intravenously or directly into the biliary tract. It works by increasing the density of the bile ducts and gallbladder, making them more visible on X-ray images. This allows for better visualization of these structures, helping in the diagnosis of various conditions such as gallstones, cholecystitis, and bile duct strictures. Research on iopydone primarily focuses on its efficacy, safety, and potential adverse effects. Studies have explored its use in various clinical settings, including the diagnosis of biliary tract diseases, evaluation of liver function, and assessment of pancreatic duct anatomy. The compound is also studied for its potential interactions with other drugs and its effects on different patient populations, including pregnant women and individuals with specific medical conditions.'

iopydone: minor descriptor (75-80); on-line & Index Medicus search IODOPYRIDONES (68-80) [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID21752
CHEMBL ID2104367
SCHEMBL ID666661
MeSH IDM0086937

Synonyms (66)

Synonym
brn 1447538
iopidona [inn-spanish]
4(1h)-pyridone, 3,5-diiodo-
nsc 135284
hytrast (van)
4(1h)-pyridinone, 3,5-diiodo-
iopydone [usan:inn:ban:jan]
jopydonum
einecs 226-969-1
iopydonum [inn-latin]
4(1h)-pyridone,5-diiodo-
iopydone
wln: t6m dvj ci ei
DJP ,
3,5-diiodo-4-pyridone
5579-93-1
3,5-diiodo-4(1h)-pyridone
nsc-135284
component of hytrast
4(1h)-pyridinone,5-diiodo-
iopydon
hytrast
nsc135284
3,5-diiodo-4-pyridinol
AC-907/25014036
3,5-diiodopyridin-4(1h)-one
7153-08-4
nsc-60547
nsc60547
4-pyridinol,5-diiodo-
3,5-diiodo-1h-pyridin-4-one
D04587
iopydone (usan)
3,5-diiodo-4-hydroxypyridine
AKOS000631308
iopidona
unii-j6b56xb19t
iopydonum
j6b56xb19t ,
AKOS015899046
CHEMBL2104367
iopydone [mart.]
iopydone [inn]
iopydone [who-dd]
iopydone [mi]
iopydone [usan]
SCHEMBL666661
3,5-diiodopyridin-4-ol
DTXSID9063954
3,5-diiodo-4-hydrox-ypyridine
smr002530268
MLS006011639
4-pyridinol, 3,5-diiodo-
component of hytrast (salt/mix)
3,5-diiodo-4(1h)-pyridinone
mfcd00023554
W12571
W18704
CS-0036290
SY040052
FT-0762575
AS-20011
4-hydroxy-3,5-diiodopyridine
Q27281264
A917903
EN300-109702

Research Excerpts

Toxicity

ExcerptReferenceRelevance
"The toxic effects of Hytrast were studied on the peritoneum of laboratory rats in order to define the lethal dose and possible causes of toxicity."( Intraperitoneal toxicity of Hytrast: an experimental study.
Ginai, AZ; Hoornstra, K; Ten Berg, RG; Ten Kate, FJ, 1986
)
0.27
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (100.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies2 (13.33%)4.05%
Observational0 (0.00%)0.25%
Other13 (86.67%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]